European Archives - Page 10 of 1607 - European Medical Journal

Ultragenyx sets $3.95m list price for fatal rare disease therapy

Ultragenyx has priced Fayuvi at $3.95m after FDA approval of the first treatment for Sanfilippo syndrome Type A.

ERS Congress Wrap 2026

The European Respiratory Society (ERS) Congress 2026 took place in Barcelona, Spain, bringing together the global respiratory community to…

The Next Generation of Melanoma Treatment: Interview with Meredith McKean

Historically, IL-2 was an effective strategy for patients; but its use was limited by toxicities…

Authentic Muslims family around the table. Iftar is the evening meal with which Muslims end their daily Ramadan fast at sunset. They break their fast at the time of the call to prayer for the evening

Ramadan Fasting Linked to Improved Liver Health in MASLD

Ramadan fasting was linked to reduced liver fat and liver injury markers in adults with MASLD, according to new research.

Degenerative cervical myelopathy

Spinal Cord DTI Predicts Balance After Cervical Surgery

Spinal cord DTI measures were associated with balance and gait function and predicted selected postoperative improvements in patients with DCM.

Woman holding pink ribbon on light background, closeup. Breast cancer awareness concept

NICE approves breast cancer drug after initial refusal

Enhertu has been recommended by NICE for NHS use in England, following an initial rejection due to cost in 2024.

An unlabeled medicine bottle, accompanied by several white pills on a pink background

4 things you need to know about new drug launches

Discover what makes clinicians embrace new drug launches and what holds them back, through HCP insights and the latest research.

Ketoacidosis Risk Persists During SGLT2 Inhibitor Use

Ketoacidosis risk with SGLT2 inhibitors varies markedly by patient factors and persists throughout treatment.

Foil blister packs of pills piled on top of each other, each with different sizes, colours and shapes of pills and oral treatments in them.

Novo signs $1.4bn deal with Orbis to create new oral treatments

Novo and Orbis Medicines join forces to develop new oral treatments for cardiometabolic diseases.

Prenatal COVID Not Linked to Most Neurodevelopmental Disorders

A cohort study of 204,663 children found prenatal COVID-19 exposure was not linked to most neurodevelopmental or neurological disorders, apart from one exception.